Hawaii
Federal Ruling Challenges FDA Restrictions on Mifepristone in Virginia
A federal judge in Virginia ruled Thursday that the U.S. Food and Drug Administration did not sufficiently justify restrictions imposed in 2023 on a drug used to terminate early pregnancies, adding another layer of complexity to a string of legal…
Last updated:
Key points
- A federal judge in Virginia ruled the FDA’s restrictions on mifepristone were unjustified.
- The ruling is part of a series of legal challenges regarding abortion medication regulations.
- Ongoing legal battles may impact future access to mifepristone across the country.
NewsWK — A federal judge in Virginia has ruled that the U.S. Food and Drug Administration (FDA) did not adequately justify its restrictions on mifepristone, a medication used to terminate early pregnancies. This ruling adds to a growing body of legal challenges concerning abortion access and the regulation of abortion medications.
The case was brought forth by abortion providers from Kansas, Montana, and Virginia, who argued that the FDA’s 2023 restrictions were excessive and inconsistent with existing legal requirements. This follows a similar ruling in Hawaii, where a federal judge also deemed the restrictions arbitrary.
U.S. District Court Judge Robert Ballou, appointed by President Biden, stated that the FDA’s review process for the 2023 regulations was insufficient. Among these regulations are requirements for pharmacies and clinicians to be specially certified, as well as mandates for prescribers and patients to sign forms acknowledging the drug’s risks. Judge Ballou wrote, “The 2023 REMS modification is unlawful and must be remanded to the FDA for review.”
Amy Hagstrom Miller, president and CEO of Whole Woman’s Health Alliance, the lead plaintiff in the case, commented that removing these restrictions would allow clinic staff to better focus on patient care rather than on “excessive paperwork.” She emphasized that these regulations do not serve a medical purpose nor enhance the experience of patients seeking abortion care.
While the FDA has not yet responded to the ruling, it is currently undertaking a broader safety review of mifepristone. The agency has indicated it may seek to dismiss cases regarding the drug’s regulation until this review is completed.
In addition to the ongoing cases in Virginia and Hawaii, there are several other legal challenges concerning mifepristone. In Louisiana, the 5th U.S. Circuit Court of Appeals is evaluating whether to overturn the provision allowing telehealth prescriptions. This ruling is critical as it could affect access to mifepristone in states with strict abortion laws.
As the legal landscape surrounding mifepristone evolves, the ongoing pressure from both pro-abortion and anti-abortion groups will likely further complicate future regulations and access to the medication.
Based on reporting by Kelcie Moseley-Morris originally published by Stateline. Read the original story.
